Literature DB >> 25673099

Short-term clinical outcomes for intermittent cold versus intermittent warm blood cardioplegia in 2200 adult cardiac surgery patients.

Karola Trescher1, Andreas Gleiss2, Michaela Boxleitner3, Wolfgang Dietl3, Hermann Kassal3, Christoph Holzinger3, Bruno K Podesser3.   

Abstract

BACKGROUND: Aim of the present study was to compare clinical outcome of intermittent cold (ICC) versus intermittent warm (IWC) blood cardioplegia in different cardiosurgical procedures.
METHODS: Two thousand one hundred and eighty-eight patients were retrospectively divided into 5 groups: isolated coronary artery bypass surgery (CABG; N.=1203), isolated aortic valve surgery (AVR; N.=374), isolated mitral valve surgery (MVR; N.=151), combined AVR+CABG (N.=390), and combined MVR+CABG (N.=70). Myocardial protection was performed by ICC (N.=1578) or IWC (N.=610) blood cardioplegia. In logistic regression models the effect of cardioplegia on 30-day mortality, IABP/ECLS (intraaortic balloon-pump/extracorporal life support) implantation, transient neurological deficit, stroke, renal failure, new-onset atrial fibrillation, and troponin T release was estimated. Potential modifications of the effect of cardioplegia by logistic EuroSCORE, cross-clamping time, ejection fraction, and op-status elective versus urgent/emergent were investigated.
RESULTS: There were no statistically significant differences between ICC and IWC regarding 30-day mortality (odds ratio [OR]=0.70; 95% CI: 0.39-1.23; P=0.219), IABP/ECLS support (OR=0.60; 95% CI: 0.23-1.55; P=0.294), transient neurological deficit (OR=0.90; 95% CI: 0.65-1.24; P=0.541), stroke (OR=0.79; 95% CI: 0.40-1.54; P=0.495), renal failure (OR=1.07; 95% CI: 0.57-1.99; P=0.825), and atrial fibrillation (OR=0.96; 95% CI: 0.77-1.18; P=0.713) across all 5 groups. Troponin t release was significantly higher in ICC compared to IWC (by 0.029±0.015 ng/mL; P=0.046) in univariate analysis; this effect was lowered by risk-factor adjustment and lost statistical significance. The effect of cardioplegia was not significantly different between groups. In urgent/emergent surgery ICC resulted in a significantly higher 30-day mortality (OR=3.03; P=0.024) compared to IWC.
CONCLUSIONS: The comparison of IWC and ICC blood cardioplegia in different cardiosurgical procedures showed no statistical significant difference in myocardial protection. The use of ICC, however, appeared overall associated with a slightly better clinical outcome except in patients undergoing urgent/emergent CABG where IWC led to a reduction in 30-day-mortality.

Entities:  

Mesh:

Year:  2015        PMID: 25673099     DOI: 10.23736/S0021-9509.16.08525-X

Source DB:  PubMed          Journal:  J Cardiovasc Surg (Torino)        ISSN: 0021-9509            Impact factor:   1.888


  4 in total

1.  Normothermic blood polarizing versus depolarizing cardioplegia in a porcine model of cardiopulmonary bypass.

Authors:  Anne-Margarethe Kramer; Attila Kiss; Stefan Heber; David J Chambers; Seth Hallström; Patrick M Pilz; Bruno K Podesser; David Santer
Journal:  Interact Cardiovasc Thorac Surg       Date:  2022-06-15

2.  MicroRNA Expression Profile Changes after Cardiopulmonary Bypass and Ischemia/Reperfusion-Injury in a Porcine Model of Cardioplegic Arrest.

Authors:  Attila Kiss; Stefan Heber; Anne-Margarethe Kramer; Matthias Hackl; Susanna Skalicky; Seth Hallström; Bruno K Podesser; David Santer
Journal:  Diagnostics (Basel)       Date:  2020-04-21

3.  Warm versus cold cardioplegia in cardiac surgery: A meta-analysis with trial sequential analysis.

Authors:  Thompson Ka Ming Kot; Jeffrey Shi Kai Chan; Saied Froghi; Dawnie Ho Hei Lau; Kara Morgan; Francesco Magni; Amer Harky
Journal:  JTCVS Open       Date:  2021-03-31

4.  Automated fastener versus manually tied knots in minimally invasive mitral valve repair: impact on operation time and short- term results.

Authors:  Martin T R Grapow; Miroslawa Mytsyk; Jens Fassl; Patrick Etter; Peter Matt; Friedrich S Eckstein; Oliver T Reuthebuch
Journal:  J Cardiothorac Surg       Date:  2015-11-03       Impact factor: 1.637

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.